City

Calgary (1)

Cleveland (1)

San Antonio (1)

Valencia (1)

Zuerich (1)

Overall Status

Recruiting (3)

Not yet recruiting (1)

Phase

phase 1/phase 2 (2)

phase 1 (1)

Sponsor

AHS Cancer Control Alberta (1)

Debiopharm International SA (1)

Juan M Garcia-Gomez (1)

Orbus Therapeutics, Inc. (1)

Collaborator

Hospital Clinico Universitario de Valencia (1)

Hospital Universitario 12 de Octubre (1)

Tom Baker Cancer Centre (1)

Intervention

temozolomide (2)

debio 0123 (1)

eflornithine (dose level -1) (1)

eflornithine (dose level 1) (1)

eflornithine (dose level 2) (1)

niacin crt (1)

radiotherapy (1)

Study Documents

Intervention Type

drug (3)

radiation (1)

Funder Type

Industry (2)

Other (2)

Study Type

Interventional (3)

Observational (1)

glioblastoma idh (isocitrate dehydrogenase) wildtype

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme Trial in Cleveland (Eflornithine (Dose Level 1), Eflornithine

Recruiting

Glioblastoma, IDH-wildtype
+4 more

Eflornithine (Dose Level 1)
+3 more

Cleveland, Ohio

The Cleveland Clinic

May 19, 2023

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III Trial in San Antonio, Zuerich (Debio 0123,

Not yet recruiting

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Astrocytoma, Grade III

Debio 0123
+2 more

San Antonio, Texas
+1 more

Mar 9, 2023

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype Trial in Calgary (Niacin CRT)

Recruiting

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Niacin CRT

Calgary, Alberta, Canada

Tom Baker Cancer Centre

Jul 18, 2022

Vascular Habitats Within Astrocytoma Grade 4 at Molecular,

Recruiting

Astrocytoma, Grade IV
+7 more

Valencia, Spain

Biomedical Data Science Lab. Universitat Politècnica de València

May 11, 2022